December 11, 2013
The Japan Society of Hepatology has revised its hepatitis C guidelines, recommending a three-drug combination therapy of simeprevir (SMV), pegylated interferon (Peg-IFN), and ribavirin (RBV) as “the first-line treatment at this point” for IFN-naïve patients and antiviral treatment-naïve elderly sufferers...read more